Luke Timmerman published this morning, an accountng of IPO performance of biotech firms to date in 2013. It looks more promising than in recent times to say the least. In 2013, of the 17 biotech IPOs, 12 have stock values that are higher than the initial offering, one is exactly the same, and 4 are down but none disasterously. It appears that IPOs are once again becoming a viable mechanism for some biotechs to raise cash.
It may or may not last. We'll have to keep following. But, its been a while since someone even suggested it was viable. See Xconomy.
Posted by Bruce Lehr June 3rd 2013.